Transfection of a human topoisomerase IIα gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide

Oncology Research

Volumn 8, Issue 3, 1996, Pages 101-110

  Asano, Takeshi ^a   An, Taeha ^a   Zwelling, Leonard A ^a   Takano, Hiroshi ^b   Fojo, Antonio T ^b   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

breast cancer; etoposide; human; promoter; topoisomerase II

Indexed keywords

AMSACRINE; DEXAMETHASONE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID; MESSENGER RNA; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MECHANISM; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

EID: 0029982520     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. 1. Osheroff, N. The enzymology of eukaryotic DNA topoisomerase II. In: Strauss, P. R., Wilson, S. H., eds. The Eukaryotic Nucleus - Molecular Biochemistry and Macromolecular Assemblies. 2nd ed. Caldwell, NJ: Tellford Press: 1990; 605-621.
2. 2. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351-375; 1989.
3. 3. Robinson, M. J.; Osheroff, N. Effect of antineoplastic drugs on the poststrand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 30:1807-1813; 1991.
4. 4. Zwelling, L. A. Topoisomerase II as a target of antileukemia drugs: a review of controversial areas. Hematol. Pathol. 3:101-112; 1989.
5. 5. Takano, H.; Kohno, K.; Ono, M.; Uchida, Y.; Kuwano, M. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res. 51:3951-3957; 1991.
6. 6. Webb, C. D.; Latham, M. D.; Lock, R. B.; Sullivan, D. M. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res. 51:6543-6549; 1991.
7. 7. Schneider, E.; Horton, J. K.; Yang, C.-H.; Nakagawa, M.; Cowan, K. H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 54:152-158; 1994.
8. 8. Ritke, M. K.; Roberts, D.; Allan, W. P.; Raymond, J.; Bergoltz, V. V.; Yalowich, J. C. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukemia K 562 cells. Br. J. Cancer 69:687-697; 1994.
9. 9. Zwelling, L. A.; Hinds, M.; Chan, D.; Mayes, J.; Sie, K. L.; Parker, E.; Silberman, L.; Radcliffe, A.; Beran, M.; Blick, M. Characterization of an amsacrine-resistant line of human leukemia cells: evidence for a drug-resistant form of topoisomerase II. J. Biol. Chem. 264: 16411-16420; 1989.
10. 10. Bugg, B. Y.; Danks, M. K.; Beck, W. T.; Suttle, D. P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc. Natl. Acad. Sci. USA. 88:7654-7658; 1991.
11. 11. Lee, M.-S., Wang, J. C., and Beran, M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J. Mol. Biol. 223:837-843; 1992.
12. 12. Chan, V. T. W.; Ng, S.-W.; Eder, J. P., Jr.; Schnipper, L. E. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from etoposide-resistant Chinese hamster ovary cell line. J. Biol. Chem. 268:2160-2165; 1993.
13. 13. Champain, J. A.; Gottesman, M. M.; Pastan, I. A novel mutant topoisomerase IIα present in VP-16-resistant human melanoma cell lines has a deletion of Alanine 429. Biochemistry 33:11327-11332; 1994.
14. 14. Eder, J. P., Jr.; Chan, V. T.-W.; Niemierko, E.; Teicher, B. A.; Schnipper, L. E. Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. J. Biol. Chem. 268:13844-13849; 1993.
15. 15. Wasserman, R. A.; Wang, J. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Cancer Res. 54:1795-1800; 1994.
16. 16. Liu, Y.-X.; Hsiung, Y.; Jannatipour, M.; Yeh, Y.; Nitiss, J. L. Yeast topoisomerase II mutants resistant to antitopoisomerases: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide. Cancer Res. 54:2943-2951; 1994.
17. 17. Asano, T.; Zwelling, L. A.; An, T.; McWatters, A.; Herzog, C. E.; Mayes, J.; Kleinerman, E. S. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumor cell line intrinsically resistant to etoposide. B. J. Cancer, in press.
18. 18. Tsai-Pflugfelder, M.; Liu, L. F.; Liu, A. A.; Tewey, K. M.; Whang-Peng, J.; Knutsen, T.; Huebner, K.; Croce, C. M.; Wang, J. C. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome 17q21-22. Proc. Acad. Natl. Sci. USA 85:7177-7181; 1988.
19. 19. Asano, T.; McWatters, A.; An, T.; Matsushima, K.; Kleinerman, E. S. Liposomal muramyl tripeptide upregulates interleukin-1α, interleukin-1β, tumor necrosis factor-α, interleukin-6 and interleukin-8 gene expression in human monocytes. J. Pharmacol. Exp. Ther. 268: 1032-1039; 1994.
20. 20. Kaufmann, S. H.; McLaughlin, S. J.; Kastan, M. B.; Liu, L. F.; Karp, J. E.; Burke, P. J. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res. 51:3534-3543; 1991.
21. 21. Hancock, K.; Tsang, V. C. W. India ink staining of proteins on nitrocellulose paper. Anal. Biochem. 113: 157-162, 1983.